valrubicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastics, daunorubicin derivatives	2805	56124-62-0

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

valrubicin
N-Trifluoroacetyladriamycin 14-valerate
valstar
N-Trifluoroacetyldoxorubicin 14-valerate
AD-32

Molecular weight: 723.65
Formula: C34H36F3NO13
CLOGP: 3.19
LIPINSKI: 2
HAC: 14
HDO: 5
TPSA: 215.22
ALOGS: -4.35
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Sept. 25, 1998	FDA	ENDO PHARM

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bladder instillation procedure	121.36	81.78	10	64	0	34956857
Urge incontinence	90.55	81.78	11	63	539	34956318

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bladder instillation procedure	142.82	82.61	11	62	0	79744315
Urge incontinence	101.59	82.61	12	61	1096	79743219

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01DB09	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D059005	Topoisomerase II Inhibitors
MeSH PA	D059003	Topoisomerase Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Malignant tumor of urinary bladder	indication	399326009	DOID:11054
Urinary tract infectious disease	contraindication	68566005
Bladder muscle dysfunction - overactive	contraindication	236633002
Rupture of bladder	contraindication	251925007
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001
Bladder Surgery	contraindication
Small Capacity Bladder	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.85	acidic
pKa2	9.66	acidic
pKa3	10.37	acidic
pKa4	12.86	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
DNA topoisomerase 2-alpha	Enzyme	P11388	TOP2A_HUMAN	INHIBITOR				WOMBAT-PK	CHEMBL

External reference:

ID	Source
4021144	VUID
N0000148597	NUI
D02697	KEGG_DRUG
4021144	VANDF
C0068314	UMLSCUI
CHEBI:135876	CHEBI
CHEMBL1096885	ChEMBL_ID
DB00385	DRUGBANK_ID
C016163	MESH_SUPPLEMENTAL_RECORD_UI
7750	INN_ID
2C6NUM6878	UNII
454216	PUBCHEM_CID
220725	RXNORM
11903	MMSL
327252	MMSL
7552	MMSL
d04356	MMSL
007694	NDDF
116079002	SNOMEDCT_US
387002006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Valrubicin Intravesical Solution	HUMAN PRESCRIPTION DRUG LABEL	1	24201-101	SOLUTION, CONCENTRATE	40 mg	INTRAVESICAL	ANDA	26 sections
Valrubicin Intravesical Solution	HUMAN PRESCRIPTION DRUG LABEL	1	24201-101	SOLUTION, CONCENTRATE	40 mg	INTRAVESICAL	ANDA	26 sections
Valstar	HUMAN PRESCRIPTION DRUG LABEL	1	67979-001	SOLUTION, CONCENTRATE	40 mg	INTRAVESICAL	NDA	26 sections
Valstar	HUMAN PRESCRIPTION DRUG LABEL	1	67979-001	SOLUTION, CONCENTRATE	40 mg	INTRAVESICAL	NDA	26 sections